Verona Pharma to Present at Two Upcoming Investor Conferences
October 31 2017 - 2:55AM
Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for respiratory diseases,
announces today that Jan-Anders Karlsson, PhD, CEO of Verona
Pharma, is scheduled to present at the following upcoming investor
conferences:
Event: Stifel 2017 Healthcare ConferenceDate: November 14,
2017Time: 11:00 AM ESTLocation: New York, NY
Event: Jefferies 2017 London Healthcare ConferenceDate: November
16, 2017Time: 2:40 PM GMT Location: London, UK
An updated version of the investor presentation will be
available in the Investors section of the Verona website
http://www.veronapharma.com/.
About Verona Pharma plc
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of respiratory diseases with
significant unmet medical needs. Verona Pharma’s product candidate,
RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 that acts as both a bronchodilator and an
anti-inflammatory agent in a single compound. In clinical trials,
treatment with RPL554 has been observed to result in statistically
significant improvements in lung function as compared to placebo,
and has shown clinically meaningful and statistically significant
improvements in lung function when administered in addition to
frequently used short- and long-acting bronchodilators as compared
to such bronchodilators administered as a single agent. Verona
Pharma is developing RPL554 for the treatment of chronic
obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and
potentially asthma.
For further information, please
contact:
Verona Pharma plc |
Tel:
+44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer |
info@veronapharma.com |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and UK
Broker) |
Tel: +44
(0) 20 7710 7600 |
Stewart Wallace / Jonathan Senior / Ben Maddison |
SNELVeronaPharma@stifel.com |
|
|
FTI
Consulting (UK Media and Investor enquiries) |
Tel:
+44 (0)20 3727 1000 |
Simon
Conway / Natalie Garland-Collins |
veronapharma@fticonsulting.com |
|
|
ICR,
Inc. (US Media and Investor enquiries) |
|
James
Heins |
Tel:
+1 203-682-8251James.Heins@icrinc.com |
Stephanie Carrington |
Tel.
+1 646-277-1282Stephanie.Carrington@icrinc.com |
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024